IL6 and macrophage activation syndrome: Therefore, the efficacy and safety of IL-6 monoclonal antibodies in the treatment of MAS in COVID-19 and in the treatment of COVID-19 itself need to be more fully evaluated through further prospective and well-designed clinical studies with larger sample sizes and long-term follow-up.